Duo Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Duo Shen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Hongyu Zhao
Department of Clinical Research Center The Second Hospital of Nanjing, Nanjing University of Chinese Medicine Nanjing China
2 shared publications - Jinyun Song
Department of Clinical Research Center The Second Hospital of Nanjing, Nanjing University of Chinese Medicine Nanjing China
2 shared publications - Wei Zhao
Medical School Southeast University Nanjing China
2 shared publications - Xuefeng Gu
Medical School Southeast University Nanjing China
2 shared publications - Yiqiong Yang
Medical School, Southeast University, Nanjing, China
2 shared publications - Ai‐Dong Gu
Department of Hepatobiliary and Pancreatic Surgery The Second Hospital of Nanjing, Nanjing University of Chinese Medicine Nanjing China
1 shared publication
Latest Publications
- Open Access
- 3 December 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (50) , 49986-49999
Systematic Analysis of Disulfidptosis-Related lncRNAs in Hepatocellular Carcinoma with Vascular Invasion Revealed That AC131009.1 Can Promote HCC Invasion and Metastasis through Epithelial–Mesenchymal Transition
Disulfidptosis, a recently identified pathway of cellular demise, served as the focal point of this research, aiming to pinpoint relevant lncRNAs that differentiate between hepatocellular carcinoma (HCC) with and without vascular invasion while also forecasting survival rates and responses to immunotherapy in patients with vascular invasion (VI+). First, we identified 300 DRLRs in the TCGA database. Subsequently, utilizing univariate analysis, LASSO-Cox proportional hazards modeling, and multivariate analytical approaches, we selected three DRLRs (AC009779.2, AC131009.1, and LUCAT1) with the highest prognostic value to construct a prognostic risk model for VI+ HCC patients. Multivariate Cox regression analysis revealed that this model is an independent prognostic factor for predicting overall survival that outperforms traditional clinicopathological factors. Pathway analysis demonstrated the enrichment of tumor and immune-related pathways in the high-risk group. Immune landscape analysis revealed that immune cell infiltration degrees and immune functions had significant differences. Additionally, we identified valuable chemical drugs (AZD4547, BMS-536924, BPD-00008900, dasatinib, and YK-4-279) for high-risk VI+ HCC patients. In-depth bioinformatics analysis was subsequently conducted to assess immune characteristics, drug susceptibility, and potential biological pathways involving the three hub DRLRs. Furthermore, the abnormally elevated transcriptional levels of the three DRLRs in HCC cell lines were validated through qRT-PCR. Functional cell assays revealed that silencing the expression of lncRNA AC131009.1 can inhibit the migratory and invasive capabilities of HCC cells, a finding further corroborated by the chorioallantoic membrane (CAM) assay. Immunohistochemical analysis and hematoxylin-eosin staining (HE) staining provided preliminary evidence that AC131009.1 may promote the invasion and metastasis of HCC cells by inducing epithelial-mesenchymal transition (EMT) in both subcutaneous xenograft models and orthotopic HCC models within nude mice. To summarize, we developed a risk assessment model founded on DRLRs and explored the potential mechanisms by which hub DRLRs promote HCC invasion and metastasis.
- 3 December 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (50) , 49986-49999
Open AccessSystematic Analysis of Disulfidptosis-Related lncRNAs in Hepatocellular Carcinoma with Vascular Invasion Revealed That AC131009.1 Can Promote HCC Invasion and Metastasis through Epithelial–Mesenchymal Transition
Disulfidptosis, a recently identified pathway of cellular demise, served as the focal point of this research, aiming to pinpoint relevant lncRNAs that differentiate between hepatocellular carcinoma (HCC) with and without vascular invasion while also forecasting survival rates and responses to immunotherapy in patients with vascular invasion (VI+). First, we identified 300 DRLRs in the TCGA database. Subsequently, utilizing univariate analysis, LASSO-Cox proportional hazards modeling, and multivariate analytical approaches, we selected three DRLRs (AC009779.2, AC131009.1, and LUCAT1) with the highest prognostic value to construct a prognostic risk model for VI+ HCC patients. Multivariate Cox regression analysis revealed that this model is an independent prognostic factor for predicting overall survival that outperforms traditional clinicopathological factors. Pathway analysis demonstrated the enrichment of tumor and immune-related pathways in the high-risk group. Immune landscape analysis revealed that immune cell infiltration degrees and immune functions had significant differences. Additionally, we identified valuable chemical drugs (AZD4547, BMS-536924, BPD-00008900, dasatinib, and YK-4-279) for high-risk VI+ HCC patients. In-depth bioinformatics analysis was subsequently conducted to assess immune characteristics, drug susceptibility, and potential biological pathways involving the three hub DRLRs. Furthermore, the abnormally elevated transcriptional levels of the three DRLRs in HCC cell lines were validated through qRT-PCR. Functional cell assays revealed that silencing the expression of lncRNA AC131009.1 can inhibit the migratory and invasive capabilities of HCC cells, a finding further corroborated by the chorioallantoic membrane (CAM) assay. Immunohistochemical analysis and hematoxylin-eosin staining (HE) staining provided preliminary evidence that AC131009.1 may promote the invasion and metastasis of HCC cells by inducing epithelial-mesenchymal transition (EMT) in both subcutaneous xenograft models and orthotopic HCC models within nude mice. To summarize, we developed a risk assessment model founded on DRLRs and explored the potential mechanisms by which hub DRLRs promote HCC invasion and metastasis.
- Open Access
- 17 May 2021
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 37 (9) , 784-794
miRNA‐10a‐5p inhibits cell metastasis in hepatocellular carcinoma via targeting SKA1
A variety of microRNAs (miRNAs) are involved in the occurrence and development of hepatocellular carcinoma (HCC). However, the role of miR‐10a‐5p in the progression of HCC remains unclear. Therefore, the purpose of this study was to determine the role of miR‐10a‐5p in the development of HCC and the possible molecular mechanism. miR‐10a‐5p expression in HCC tissues and plasma from patients was detected by quantitative real‐time polymerase chain reaction. Migratory changes in HCC cells were detected after the overexpression of miR‐10a‐5p. Epithelial–mesenchymal transition (EMT)‐related proteins were detected by Western blot. Finally, through luciferase assay and rescue experiments, the mechanism by which miR‐10a‐5p regulates its downstream gene, human spindle and kinetochore‐associated complex subunit 1, SKA1 and the interaction between these molecules in the development of HCC were determined. The expression of miR‐10a‐5p was markedly downregulated in HCC tissues, cell lines, and plasma. The overexpression of miR‐10a‐5p significantly inhibited the migration, invasion, and EMT of HCC cells. Furthermore, SKA1 was shown to be a downstream gene of miR‐10a‐5p. SKA1 silencing had the same effect as miR‐10a‐5p overexpression in HCC. In particular, the overexpression of SKA1 reversed the inhibitory effects of miR‐10a‐5p in HCC. Taken together, low miR‐10a‐5p expression is associated with HCC progression. miR‐10a‐5p inhibits the malignant development of HCC by negatively regulating SKA1.
- 17 May 2021
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 37 (9) , 784-794
Open AccessmiRNA‐10a‐5p inhibits cell metastasis in hepatocellular carcinoma via targeting SKA1
A variety of microRNAs (miRNAs) are involved in the occurrence and development of hepatocellular carcinoma (HCC). However, the role of miR‐10a‐5p in the progression of HCC remains unclear. Therefore, the purpose of this study was to determine the role of miR‐10a‐5p in the development of HCC and the possible molecular mechanism. miR‐10a‐5p expression in HCC tissues and plasma from patients was detected by quantitative real‐time polymerase chain reaction. Migratory changes in HCC cells were detected after the overexpression of miR‐10a‐5p. Epithelial–mesenchymal transition (EMT)‐related proteins were detected by Western blot. Finally, through luciferase assay and rescue experiments, the mechanism by which miR‐10a‐5p regulates its downstream gene, human spindle and kinetochore‐associated complex subunit 1, SKA1 and the interaction between these molecules in the development of HCC were determined. The expression of miR‐10a‐5p was markedly downregulated in HCC tissues, cell lines, and plasma. The overexpression of miR‐10a‐5p significantly inhibited the migration, invasion, and EMT of HCC cells. Furthermore, SKA1 was shown to be a downstream gene of miR‐10a‐5p. SKA1 silencing had the same effect as miR‐10a‐5p overexpression in HCC. In particular, the overexpression of SKA1 reversed the inhibitory effects of miR‐10a‐5p in HCC. Taken together, low miR‐10a‐5p expression is associated with HCC progression. miR‐10a‐5p inhibits the malignant development of HCC by negatively regulating SKA1.
- Open Access
- 1 January 2020
- Published by The Korean Gastric Cancer Association in Journal of Gastric Cancer
- Vol. 20 (3) , 300-312
Circular RNA hsa_circ_0005556 Accelerates Gastric Cancer Progression by Sponging miR-4270 to Increase MMP19 Expression
Shen D, et al. J Gastric Cancer. 2019 Sep;20:e28. https://doi.org/10.5230/jgc.2020.20.e28
- 1 January 2020
- Published by The Korean Gastric Cancer Association in Journal of Gastric Cancer
- Vol. 20 (3) , 300-312
Open AccessCircular RNA hsa_circ_0005556 Accelerates Gastric Cancer Progression by Sponging miR-4270 to Increase MMP19 Expression
Shen D, et al. J Gastric Cancer. 2019 Sep;20:e28. https://doi.org/10.5230/jgc.2020.20.e28
- Open Access
- 5 March 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 15 (5) , 6361-6367
miR-130b-5p promotes proliferation, migration and invasion of gastric cancer cells via targeting RASAL1
The aim of the present study was to investigate the targeted interaction between microRNA (miR)‑130b‑5p and RAS protein activator like 1 (RASAL1) gene and elucidate the function of miR‑130b‑5p in cell proliferation, migration and invasion in gastric cancer. Expression of miR‑130b‑5p and RASAL1 in seven gastric cell lines was detected by reverse transcription-quantitative polymerase chain reaction (RT‑qPCR). MGC803 cells were selected for further study since they exhibited a marked increase in expression of miR‑130b‑5p accompanied by decreased expression of RASAL1. MGC803 cells were transfected with miR‑130b‑5p mimics and miR‑130b‑5p inhibitor using Lipofectamine 2000 for over‑ and underexpression, respectively, with cells transfected with negative control (NC) sequence as the control. In addition, a luciferase reporter gene assay was performed to evaluate the targeted interaction between miR‑130b‑5p and RASAL1. Then, alterations in RASAL1 expression were detected by RT‑qPCR and western blot analysis following transfection with miR‑130b‑5p mimics and miR‑130b‑5p inhibitor. Cell proliferation, colony formation, and migration and invasion ability were detected by MTT, colony formation and Transwell assays, respectively. RASAL1 was demonstrated to be a target gene of miR‑130b‑5p by luciferase reporter gene assay. In addition, the expression of RASAL1 was significantly lower in MGC803 cells that were transfected with miR‑130b‑5p mimics and significantly higher in cells transfected with miR‑130b‑5p inhibitor in comparison with cells transfected with NC (P<0.05). Furthermore, the experimental group transfected with miR‑130b‑5p mimics manifested significantly higher cell proliferation, increased colony formation and increased migratory and invasive capacities (P<0.05). By contrast, cells transfected with miR‑130b‑5p inhibitor exhibited significantly lower cell proliferation, decreased colony formation and decreased migratory and invasive capacities, compared with cells transfected with NC (P<0.05). In conclusion, RASAL1 was demonstrated to be a target gene of miR‑130b‑5p. Overexpression of miR‑130b‑5p results in promoted proliferation, colony formation and migration and invasion abilities through targeted modulation of RASAL1.
- 5 March 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 15 (5) , 6361-6367
Open AccessmiR-130b-5p promotes proliferation, migration and invasion of gastric cancer cells via targeting RASAL1
The aim of the present study was to investigate the targeted interaction between microRNA (miR)‑130b‑5p and RAS protein activator like 1 (RASAL1) gene and elucidate the function of miR‑130b‑5p in cell proliferation, migration and invasion in gastric cancer. Expression of miR‑130b‑5p and RASAL1 in seven gastric cell lines was detected by reverse transcription-quantitative polymerase chain reaction (RT‑qPCR). MGC803 cells were selected for further study since they exhibited a marked increase in expression of miR‑130b‑5p accompanied by decreased expression of RASAL1. MGC803 cells were transfected with miR‑130b‑5p mimics and miR‑130b‑5p inhibitor using Lipofectamine 2000 for over‑ and underexpression, respectively, with cells transfected with negative control (NC) sequence as the control. In addition, a luciferase reporter gene assay was performed to evaluate the targeted interaction between miR‑130b‑5p and RASAL1. Then, alterations in RASAL1 expression were detected by RT‑qPCR and western blot analysis following transfection with miR‑130b‑5p mimics and miR‑130b‑5p inhibitor. Cell proliferation, colony formation, and migration and invasion ability were detected by MTT, colony formation and Transwell assays, respectively. RASAL1 was demonstrated to be a target gene of miR‑130b‑5p by luciferase reporter gene assay. In addition, the expression of RASAL1 was significantly lower in MGC803 cells that were transfected with miR‑130b‑5p mimics and significantly higher in cells transfected with miR‑130b‑5p inhibitor in comparison with cells transfected with NC (P<0.05). Furthermore, the experimental group transfected with miR‑130b‑5p mimics manifested significantly higher cell proliferation, increased colony formation and increased migratory and invasive capacities (P<0.05). By contrast, cells transfected with miR‑130b‑5p inhibitor exhibited significantly lower cell proliferation, decreased colony formation and decreased migratory and invasive capacities, compared with cells transfected with NC (P<0.05). In conclusion, RASAL1 was demonstrated to be a target gene of miR‑130b‑5p. Overexpression of miR‑130b‑5p results in promoted proliferation, colony formation and migration and invasion abilities through targeted modulation of RASAL1.